NCT04870853View on ClinicalTrials.gov

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions
Recurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Aggressive B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
OTHER

Electronic Health Record Review

Medical records reviewed

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER